Overview

Study Evaluating Bifeprunox in Patients With Schizophrenia.

Status:
Terminated
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
An open-label extension study using a variable dose (20 to 30 mg daily) of bifeprunox to evaluate long-term safety.
Phase:
Phase 3
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer